KEGG   DRUG: Inclisiran sodium
Entry
D12293                      Drug                                   
Name
Inclisiran sodium (JAN);
Leqvio (TN)
Product
LEQVIO (Novartis Pharmaceuticals Corporation)
Formula
C529H664F12N176O316P43S6. 43Na
Exact mass
17276.375
Mol weight
17284.7247
Class
Hypolipidemic agent
 DG01946  Hypolipidemic agent
  DG03128  Anti-PCSK9 antibody and siRNA
Remark
ATC code: C10AX16
Chemical structure group: DG03216
Product (DG03216): D12293<US>
Efficacy
Antihyperlipidemic, Translation inhibitor
  Disease
Heterozygous familial hypercholesterolemia [DS:H00155]
Atherosclerotic cardiovascular disease [DS:H02505]
Target
PCSK9 [HSA:255738] [KO:K13050]
  Pathway
hsa04979  Cholesterol metabolism
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C10 LIPID MODIFYING AGENTS
   C10A LIPID MODIFYING AGENTS, PLAIN
    C10AX Other lipid modifying agents
     C10AX16 Inclisiran
      D12293  Inclisiran sodium (JAN) <US>
USP drug classification [BR:br08302]
 Cardiovascular Agents
  Dyslipidemics, Other
   Inclisiran
    D12293  Inclisiran sodium (JAN)
Drug groups [BR:br08330]
 Hypolipidemic agent
  DG01946  Hypolipidemic agent
   DG03128  Anti-PCSK9 antibody and siRNA
    DG03216  Inclisiran
     D12293  Inclisiran sodium
Drug classes [BR:br08332]
 Cardiovascular agent
  DG01946  Hypolipidemic agent
   D12293  Inclisiran sodium
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Serine peptidases
    PCSK9
     D12293  Inclisiran sodium (JAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D12293
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D12293
Drug groups [BR:br08330]
 Hypolipidemic agent
  DG01946  Hypolipidemic agent
   DG03128  Anti-PCSK9 antibody and siRNA
    DG03216  Inclisiran
Other DBs
CAS: 1639324-62-1
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system